E4NA.F AROVELLA THERAPEUTICS
- Market cap
- EUR 33.8M
- P/E
- -
- P/B
- 3.81x
- ROE
- -48.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is E4NA.F undervalued?
Graham numberThe Graham number of AROVELLA THERAPEUTICS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AROVELLA THERAPEUTICS fundamental analysis
No fundamental analysis for AROVELLA THERAPEUTICS yet.
AROVELLA THERAPEUTICS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AROVELLA THERAPEUTICS
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer…
Full company profileAROVELLA THERAPEUTICS financial statements
AROVELLA THERAPEUTICS annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 296K | 406K | 17.0K | 136K | - |
| Gross Profit | 88.8K | 202K | 17.0K | 136K | - |
| Operating Income | -7.60M | -9.68M | -10.8M | -11.2M | -11.2M |
| EBITDA | - | -9.32M | -8.69M | -11.1M | -11.1M |
| Net Income | -8.62M | -10.2M | -8.75M | -7.51M | -6.92M |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||
| Total Assets | 8.89M | 5.50M | 13.3M | 21.6M | 15.0M |
| Total Liabilities | 1.89M | 2.00M | 2.15M | 1.52M | 857K |
| Shareholders' Equity | 7.62M | 3.78M | 11.2M | 20.1M | 14.2M |
| Cash & Short-term Investments | 6.07M | 5.18M | 12.7M | 20.9M | 14.4M |
| Cash Flow | |||||
| Capital Expenditure | 566K | 2.72K | 129K | 413K | 39.3K |
| Free Cash Flow | -6.83M | -6.40M | -7.04M | -7.34M | -6.95M |
| Ratios | |||||
| ROE | -113.2% | -269.3% | -77.9% | -37.4% | -48.9% |
| ROA | -97.0% | -185.0% | -65.8% | -34.8% | -46.1% |
| Net Profit Margin | -2,914.2% | -2,508.4% | -51,447.3% | -5,521.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AROVELLA THERAPEUTICS dividends
AROVELLA THERAPEUTICS has not paid dividends in the last 6 fiscal years.
Last stock split: 1:25 on Nov 14, 2019.
Who owns AROVELLA THERAPEUTICS
- Insiders 23.48%
- Institutions 16.20%
- Public & others 60.33%
- Shares outstanding 1.21B
- Free float 928M
AROVELLA THERAPEUTICS company profile
- Company name
- AROVELLA THERAPEUTICS
- Ticker
- E4NA.F
- ISIN
- AU0000182784
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Corporate One, Preston, VIC, Australia, 3072
- Phone
- 61 3 9863 6472
- Website
- arovella.com
About AROVELLA THERAPEUTICS
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
AROVELLA THERAPEUTICS management
4- Mr. Lachie MalliaCFO & Company Secretary
- Ms. Michelle LongSenior Administration Manager
- Dr. Robson DossaSenior Vice President of Manufacturing & Quality
- Dr. Michelle FergusonSenior Director of Research & Development